Navigation Links
Tobira's Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
Date:2/17/2010

SAN FRANCISCO, Feb. 17 /PRNewswire/ -- The first-ever-reported Phase II data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, demonstrate that the CCR5 receptor antagonist provides potent antiviral activity and is generally safe and well-tolerated in its proof of concept trial. The data were released here today in an oral presentation at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).

In a Phase IIa trial involving 54 treatment-experienced HIV infected patients, a 10-day course of once-daily, TBR-652 monotherapy produced a median nadir decline from baseline in HIV viral load of up to 1.8 log10 copies/mL. There were no serious adverse events, deaths or study drug-related discontinuations in the study.  Dose dependent changes in MCP-1 concentrations were also observed, demonstrating TBR-652's dual CCR5/CCR2 mechanism of action and potential anti-inflammatory benefits.  

"These data demonstrate that TBR-652 offers potent viral suppression and excellent safety and tolerability in this short-term study," observed Calvin J. Cohen, M.D., M.Sc., of the Community Research Initiative of New England. "This compound provides the potential for once-daily dosing, without the need for a pharmacologic boosting agent, an important benefit for simplified dosing and ease of administration in early stage disease."

Dr. Cohen presented data from Study 652-2-201, a double-blind, placebo-controlled, dose-escalation trial in which patients were randomized four-to-one to receive doses of TBR-652 of 25mg, 50mg, 75mg, 100mg, 150mg and placebo.  

All patients were HIV treatment-experienced, though none had previously been treated with a CCR5 antagonist. Most adverse events in the study were mild in severity (Grade 1). There were no clinically significant trends in adverse events, laboratory tests, vital signs, or electrocardiogram measurements. Additionally, there were no liver function test elevations greater than Grade 1.

The antiviral activity of TBR-652, as evidenced by reductions in HIV viral load, is outlined in the following dose-escalation chart:

    
    
                     Median change from        
                    baseline after 10 days  Median nadir change from   
    Dosing cohort    (log10 copies/mL)      baseline (log10 copies/ mL)
    -------------  ----------------------   --------------------------
                  
    25 mg                  -0.5                     -0.7
    -----                  ----                     ----
    50 mg                  -1.3                     -1.7
    -----                  ----                     ----
    75 mg                  -1.6                     -1.8
    -----                  ----                     ----
    100 mg                 -1.2                     -1.4
    ------                 ----                     ----
    150 mg                 -1.5                     -1.7
    ------                 ----                     ----
    placebo                +0.1                     -0.2
    -------                ----                     ----
    
    

Dr. Cohen noted that all patients in the 75-mg dosing group achieved a decline in HIV-1 RNA of at least 1.0 log10 copies/mL.  

"Today's data presentation represents an exciting milestone for Tobira," said James Sapirstein, President and CEO of Tobira Therapeutics. "TBR-652's unique properties, including once-daily dosing that may facilitate co-formulation with other antiretrovirals, such as nucleoside-sparing or ritonavir-sparing combinations, distinguish it from the early CCR5 antagonists.  Further, TBR-652's added CCR2 antagonism and potential anti-inflammatory benefits suggests a bright future for this high-potential compound."

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease.  The company was founded in 2006 by Eckard Weber, MD, a partner at Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

www.tobiratherapeutics.com

SOURCE Tobira Therapeutics, Inc.

RELATED LINKS
http://www.tobiratherapeutics.com

'/>"/>

SOURCE Tobira Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Oclaro Next-Generation Orion Fiber-Coupled Diode Laser Raises the Bar for Performance, Cost and Reliability for Solid State Lasers
2. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
3. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
4. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
5. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
6. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
9. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
10. ISTA Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Once-Daily XiDay(TM)
11. Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):